Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BCDA

BioCardia Inc

Feb 11 • 03:36PM ET

1.20

-0.05 -4.40 %

Healthcare • Biotechnology • USA • NASD

Feb 10, 9:21 AMBioCardia announces it has completed an FDA Q-Submission Pre-Submission seeking approval of its Helix Transendocardial Delivery Catheter for intramyocardial therapeutic and diagnostic agent delivery.

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	55.02%	Shs Outstand	10.61M	Perf Week	9.63%
Market Cap	12.69M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	14.61%	Shs Float	4.77M	Perf Month	-15.85%
Enterprise Value	8.04M	PEG	-	EPS next Q	-0.17	Inst Own	5.70%	Short Float	4.89%	Perf Quarter	-7.36%
Income	-8.54M	P/S	-	EPS this Y	58.62%	Inst Trans	2.93%	Short Ratio	2.98	Perf Half Y	-31.32%
Sales	0.00M	P/B	4.83	EPS next Y	31.67%	ROA	-137.58%	Short Interest	0.23M	Perf YTD	-4.40%
Book/sh	0.25	P/C	2.40	EPS next 5Y	34.77%	ROE	-317.47%	52W High	3.20 -62.66%	Perf Year	-52.39%
Cash/sh	0.50	P/FCF	-	EPS past 3/5Y	36.28% 40.58%	ROIC	-300.92%	52W Low	1.00 19.50%	Perf 3Y	-96.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-61.48% -39.41%	Gross Margin	-	Volatility	9.41% 6.36%	Perf 5Y	-98.40%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	58.50%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-98.96%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	42.12	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.62	EPS Q/Q	61.55%	SMA20	-6.51%	Beta	0.60	Target Price	15.50
Payout	-	Debt/Eq	0.24	Sales Q/Q	-	SMA50	-9.01%	Rel Volume	1.12	Prev Close	1.25
Employees	20	LT Debt/Eq	0.08	Earnings	Nov 12 AMC	SMA200	-31.83%	Avg Volume	78.43K	Price	1.20
IPO	Nov 13, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	-4.35% -	Trades		Volume	82,619	Change	-4.40%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Feb-10-26 09:15AM	BioCardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart (GlobeNewswire)
Feb-03-26 08:00AM	BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire)
Dec-16-25 08:00AM	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA (GlobeNewswire)
Dec-03-25 08:00AM	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno (GlobeNewswire)
Dec-01-25 08:30AM	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress (GlobeNewswire)
08:15AM	Loading…
Nov-24-25 08:15AM	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality (GlobeNewswire)
Nov-12-25 04:40PM	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Nov-10-25 08:30AM	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Nov-05-25 07:29PM	BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
08:00AM	Loading…
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
05:45AM	Loading…
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Feb 04 '26	Buy	1.13	5,000	5,650	273,866	Feb 04 05:47 PM
Altman Peter	President and CEO	Jan 20 '26	Buy	1.32	600	792	268,566	Jan 21 05:03 PM
Altman Peter	President and CEO	Jan 21 '26	Buy	1.34	300	402	268,866	Jan 21 05:03 PM
Altman Peter	President and CEO	Dec 17 '25	Buy	1.30	900	1,170	267,966	Dec 17 06:32 PM
Altman Peter	President and CEO	Dec 16 '25	Buy	1.37	200	274	267,066	Dec 17 06:32 PM
STERTZER SIMON H	Director	Sep 19 '25	Buy	1.25	398,400	498,000	591,054	Sep 23 09:00 AM
Blank Andrew Scott	Director	Sep 19 '25	Buy	1.25	288,000	360,000	634,023	Sep 23 09:00 AM
Altman Peter	President and CEO	Sep 19 '25	Buy	1.25	48,000	60,000	216,762	Sep 23 09:00 AM
Altman Peter	President and CEO	Aug 22 '25	Buy	1.83	700	1,281	168,762	Aug 25 09:30 AM
Altman Peter	President and CEO	Aug 13 '25	Buy	1.83	100	183	168,062	Aug 13 06:59 PM
Altman Peter	President and CEO	Aug 12 '25	Buy	1.75	400	700	167,962	Aug 12 07:23 PM
Altman Peter	President and CEO	Aug 11 '25	Buy	1.76	1,700	2,989	167,562	Aug 11 07:21 PM
McClung David	Chief Financial Officer	Jun 30 '25	Buy	2.08	4,819	9,999	47,950	Jul 02 09:03 PM
Altman Peter	President and CEO	Jun 30 '25	Buy	2.08	24,096	49,999	165,862	Jul 02 09:02 PM
STERTZER SIMON H	Director	Jun 30 '25	Buy	2.08	72,289	150,000	192,654	Jul 02 09:02 PM
Blank Andrew Scott	Director	Jun 30 '25	Buy	2.08	72,289	150,000	346,023	Jul 02 09:01 PM
Altman Peter	President and CEO	May 30 '25	Buy	2.21	100	221	141,766	May 30 08:55 PM
Altman Peter	President and CEO	May 20 '25	Buy	2.08	1,600	3,328	140,966	May 22 06:45 PM
Altman Peter	President and CEO	May 22 '25	Buy	1.89	700	1,323	141,666	May 22 06:45 PM
Altman Peter	President and CEO	May 16 '25	Buy	2.43	300	730	139,366	May 16 05:31 PM
Altman Peter	President and CEO	May 14 '25	Buy	2.99	100	299	139,066	May 16 05:31 PM
KRASNO RICHARD M	Director	Apr 23 '25	Buy	1.91	13,123	24,999	16,268	Apr 28 06:46 PM
McClung David	Chief Financial Officer	Apr 23 '25	Buy	1.91	13,123	24,999	43,131	Apr 25 09:38 PM
Facteau Bill	Director	Apr 23 '25	Buy	1.91	13,123	24,999	13,123	Apr 25 09:37 PM
Blank Andrew Scott	Director	Apr 23 '25	Buy	1.91	131,233	249,999	265,957	Apr 25 09:36 PM
STERTZER SIMON H	Director	Apr 23 '25	Buy	1.91	104,986	199,998	120,365	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 23 '25	Buy	1.91	26,246	49,999	138,966	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 15 '25	Buy	2.14	100	214	112,720	Apr 17 07:44 PM
Altman Peter	President and CEO	Apr 11 '25	Buy	2.03	300	609	112,620	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 10 '25	Buy	1.99	300	597	112,320	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 07 '25	Buy	1.96	500	980	112,020	Apr 08 05:01 PM
Altman Peter	President and CEO	Apr 04 '25	Buy	2.04	800	1,632	111,520	Apr 07 05:10 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.20	600	1,320	110,720	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 02 '25	Buy	2.23	500	1,115	110,120	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.24	1,200	2,688	109,620	Apr 03 09:08 PM
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM

Open in Screener

OPK

Opko Health Inc

Feb 11 • 03:37PM ET

1.24

+0.02 1.64 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: LH DGX MYGN EXAS MEDP CMRX VNDA BCRX TECH CRL

| Held by: IWM VTI VB VXF IWN IBB VBR VTWO SCHA VBK

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	49.06%	Shs Outstand	768.70M	Perf Week	-0.80%
Market Cap	951.95M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.65%	Shs Float	391.08M	Perf Month	-6.77%
Enterprise Value	932.17M	PEG	-	EPS next Q	-0.07	Inst Own	26.74%	Short Float	7.90%	Perf Quarter	-6.77%
Income	-180.42M	P/S	1.48	EPS this Y	-314.58%	Inst Trans	-3.97%	Short Ratio	9.21	Perf Half Y	-6.06%
Sales	642.03M	P/B	0.73	EPS next Y	22.04%	ROA	-8.49%	Short Interest	30.88M	Perf YTD	-1.59%
Book/sh	1.70	P/C	2.29	EPS next 5Y	-20.51%	ROE	-13.32%	52W High	2.04 -39.07%	Perf Year	-23.46%
Cash/sh	0.54	P/FCF	-	EPS past 3/5Y	-18.15% 32.04%	ROIC	-10.76%	52W Low	1.11 11.71%	Perf 3Y	-0.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-26.21% -4.59%	Gross Margin	22.96%	Volatility	2.62% 3.90%	Perf 5Y	-77.54%
Dividend TTM	-	EV/Sales	1.45	EPS Y/Y TTM	-31.28%	Oper. Margin	-33.30%	ATR (14)	0.05	Perf 10Y	-84.50%
Dividend Ex-Date	-	Quick Ratio	3.32	Sales Y/Y TTM	-9.75%	Profit Margin	-28.10%	RSI (14)	41.61	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	3.70	EPS Q/Q	11.24%	SMA20	-2.94%	Beta	1.49	Target Price	3.56
Payout	-	Debt/Eq	0.30	Sales Q/Q	-12.65%	SMA50	-5.17%	Rel Volume	0.32	Prev Close	1.22
Employees	2997	LT Debt/Eq	0.28	Earnings	Oct 29 AMC	SMA200	-8.61%	Avg Volume	3.35M	Price	1.24
IPO	Nov 02, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	150.00% -5.65%	Trades		Volume	1,010,595	Change	1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-25	Initiated	JP Morgan	Neutral
Oct-31-25	Downgrade	Jefferies	Buy → Hold	$1.60
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50
May-30-13	Reiterated	Ladenburg Thalmann	Buy	$8.50 → $10

Show Previous Ratings

Feb-06-26 11:02AM	Opko Health (OPK) Expands Entera Partnership for Drug Co-Development (Insider Monkey)
Feb-04-26 08:00AM	OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism (GlobeNewswire)
Jan-13-26 04:43AM	OrthoPediatrics (KIDS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Jan-06-26 04:11PM	OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:05AM	OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth (Zacks)
07:28AM	Loading…
Dec-09-25 07:28AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now (Zacks)
Nov-20-25 09:40AM	Astera initiated, Nasdaq upgraded: Wall Street's top analyst calls (The Fly)
Nov-19-25 04:05PM	OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:03AM	NextPlat Reports Third Quarter 2025 Results (PR Newswire)
Oct-30-25 11:29PM	Opko Health Inc.'s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals (Insider Monkey) -6.85%
12:24PM	OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands (Zacks)
Oct-29-25 06:30PM	Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics (Zacks)
05:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
04:42PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Loading…
08:00AM	OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications (GlobeNewswire)
Oct-28-25 08:00AM	OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers (GlobeNewswire)
Oct-23-25 01:56PM	Here's Why You Should Add OPKO Health Stock to Your Portfolio (Zacks)
Oct-22-25 04:05PM	OPKO Health to Report Third Quarter 2025 Financial Results on October 29 (GlobeNewswire)
Oct-01-25 01:44PM	OPKO Health, Inc. (OPK)'s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1 (Insider Monkey)
Sep-17-25 08:52AM	LH Stock Rises on Acquisition of BioReference Health's Select Assets (Zacks)
Sep-15-25 08:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Sep-11-25 12:20PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Aug-17-25 06:23PM	OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics (Insider Monkey)
Aug-08-25 04:05PM	Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 03:27PM	RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment. (Barrons.com)
Aug-04-25 10:01AM	Opko Health (OPK) Reports Fiscal Q2 2025 Results (Insider Monkey) +6.72%
Aug-01-25 12:20PM	OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands (Zacks) -7.03%
06:47AM	OPKO Health (OPK) to Present Short Bowel Syndrome Treatment in Prague (Insider Monkey)
Jul-31-25 07:00PM	Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics (Zacks)
05:45PM	Loading…
05:45PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:45PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	OPKO Health to Report Second Quarter 2025 Financial Results on July 31 (GlobeNewswire)
Jul-23-25 11:25AM	OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) (Insider Monkey)
Jul-08-25 08:00AM	OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress (GlobeNewswire)
Jul-07-25 09:10AM	H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 (Insider Monkey)
Jun-25-25 11:00AM	OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium (GlobeNewswire)
08:00AM	OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting (GlobeNewswire)
Jun-24-25 03:52PM	Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT (Insider Monkey)
Jun-13-25 12:37PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Jun-09-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development (GlobeNewswire)
May-15-25 08:00AM	OPKO Health to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-01-25 12:43PM	OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands (Zacks)
08:57AM	Q1 2025 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Apr-30-25 07:52PM	OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-25 09:35AM	Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround (Zacks)
Apr-17-25 09:38AM	Labcorp Holdings: Regaining Credibility (Seeking Alpha)
08:00AM	OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 (GlobeNewswire)
Apr-11-25 04:05PM	NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program (PR Newswire)
Apr-04-25 08:00AM	OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program (GlobeNewswire)
Mar-28-25 09:35AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Mar-14-25 06:59PM	Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. (Barrons.com)
12:07PM	Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? (Insider Monkey)
Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
Feb-27-25 10:45PM	Opko Health (OPK) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00PM	OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates (Zacks)
05:58PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Feb-25-25 09:15AM	Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-13-25 04:05PM	OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-12-25 09:15AM	Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-20-25 10:02PM	OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential (Insider Monkey)
Jan-09-25 11:45AM	OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck (GlobeNewswire)
Dec-11-24 02:08AM	Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? (Insider Monkey)
Dec-10-24 08:00AM	NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer (PR Newswire)
Nov-29-24 02:43PM	Sleep Number, Getty Images, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-20-24 08:00AM	OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo (PR Newswire)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-14-24 06:00AM	NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results (PR Newswire)
Nov-08-24 04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
04:01AM	OPKO Health Inc (OPK) Q3 2024 Earnings Call Highlights: A Turnaround in Profitability Amidst ... (GuruFocus.com)
Nov-07-24 10:15PM	Opko Health (OPK) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings (Zacks)
06:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
05:35PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference to Include OvaWatch (GlobeNewswire)
Oct-29-24 04:05PM	OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire) +6.67% -5.00%
Oct-07-24 08:00AM	NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan (PR Newswire)
08:00AM	ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-23-24 08:00AM	OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development (GlobeNewswire)
Sep-16-24 07:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health (PR Newswire)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 21 '25	Buy	1.33	580,000	768,807	216,706,448	Nov 21 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 20 '25	Buy	1.33	580,000	771,328	216,126,448	Nov 20 06:10 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 19 '25	Buy	1.31	580,000	759,115	215,546,448	Nov 19 05:02 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 18 '25	Buy	1.27	533,300	678,906	214,966,448	Nov 18 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Oct 31 '25	Buy	1.42	150,000	213,435	214,386,448	Oct 31 05:15 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Aug 08 '25	Buy	1.32	675,000	891,000	214,676,448	Aug 08 04:56 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 10 '25	Buy	1.36	125,000	169,712	214,001,448	Apr 10 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 08 '25	Buy	1.48	125,000	184,650	213,876,448	Apr 08 05:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 01 '25	Buy	1.65	100,000	164,850	213,751,448	Apr 01 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 28 '25	Buy	1.70	150,000	254,385	213,651,448	Mar 28 05:22 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 17 '25	Buy	1.74	200,000	347,820	213,501,448	Mar 17 05:27 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 28 '25	Buy	1.71	67,434	115,312	213,301,448	Feb 28 07:34 PM

BCDA

BioCardia Inc

OPK

Opko Health Inc

Upgrade your FINVIZ experience